SOPHiA GENETICS (SOPH) Aandelenoverzicht
SOPHiA GENETICS SA is een cloud-native softwaretechnologiebedrijf in de gezondheidszorg. Meer informatie
| Sneeuwvlok Score | |
|---|---|
| Waardering | 0/6 |
| Toekomstige groei | 2/6 |
| Prestaties in het verleden | 0/6 |
| Financiële gezondheid | 5/6 |
| Dividenden | 0/6 |
Beloningen
Risicoanalyse
SOPH Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
SOPHiA GENETICS SA Concurrenten
Prijsgeschiedenis en prestaties
| Historische aandelenkoersen | |
|---|---|
| Huidige aandelenkoers | US$7.68 |
| 52 Week Hoogtepunt | US$8.98 |
| 52 Week Laag | US$3.10 |
| Bèta | 0.98 |
| 1 maand verandering | 0.13% |
| 3 maanden verandering | 47.69% |
| 1 Jaar Verandering | 132.02% |
| 3 jaar verandering | 231.03% |
| 5 jaar verandering | -52.68% |
| Verandering sinds IPO | -54.18% |
Recent nieuws en updates
Narratiefupdate • Sep 03
SOPH: AstraZeneca Partnerships And AI Usage Model Will Drive Future Upside
The analyst price target for SOPHiA GENETICS has been revised higher from $9.00 to $9.75, with analysts pointing to recent Q2 performance, expanded AstraZeneca and companion diagnostics partnerships, accelerating U.S. uptake, and the company’s usage based revenue model across a $40b addressable market as key supports for this updated view. Analyst Commentary Recent research on SOPHiA GENETICS highlights a mix of enthusiasm for the company’s positioning in data driven oncology and rare disease diagnostics, alongside typical execution questions around growth, adoption, and profitability timing.
Narratiefupdate • Aug 18
SOPH: Astrazeneca Partnerships And AI Platform Will Drive Future Oncology Opportunity
Analysts have lifted the SOPHiA GENETICS analyst price target from $12 to $14, citing recent Street research that highlights stronger Q2 results, a raised outlook, major AstraZeneca and companion diagnostics partnerships, growing U.S. adoption, and recurring, usage based revenue streams across clinical and biopharma markets as key supports for this updated view. Analyst Commentary Bullish analysts see SOPHiA GENETICS as a company that is executing on its plan, with recent research pointing to what they view as strong Q2 results, a raised outlook, and expanding commercial traction.Recent updates
Narratiefupdate • Sep 03
SOPH: AstraZeneca Partnerships And AI Usage Model Will Drive Future Upside
The analyst price target for SOPHiA GENETICS has been revised higher from $9.00 to $9.75, with analysts pointing to recent Q2 performance, expanded AstraZeneca and companion diagnostics partnerships, accelerating U.S. uptake, and the company’s usage based revenue model across a $40b addressable market as key supports for this updated view. Analyst Commentary Recent research on SOPHiA GENETICS highlights a mix of enthusiasm for the company’s positioning in data driven oncology and rare disease diagnostics, alongside typical execution questions around growth, adoption, and profitability timing.Narratiefupdate • Aug 18
SOPH: Astrazeneca Partnerships And AI Platform Will Drive Future Oncology Opportunity
Analysts have lifted the SOPHiA GENETICS analyst price target from $12 to $14, citing recent Street research that highlights stronger Q2 results, a raised outlook, major AstraZeneca and companion diagnostics partnerships, growing U.S. adoption, and recurring, usage based revenue streams across clinical and biopharma markets as key supports for this updated view. Analyst Commentary Bullish analysts see SOPHiA GENETICS as a company that is executing on its plan, with recent research pointing to what they view as strong Q2 results, a raised outlook, and expanding commercial traction.Narratiefupdate • Aug 04
SOPH: AI Multimodal Data Platform Will Drive Future Oncology Opportunity
Analysts have raised their price target on SOPHiA GENETICS from $9 to $12, citing the company's AI-driven use of multimodal genomic and clinical data, its recurring usage-based revenue model across clinical and biopharma customers, and its exposure to an estimated $40 billion market. What’s in the News for SOPHiA GENETICS SOPHiA GENETICS filed and then completed a follow on equity offering of common stock, raising US$49.9985 million through 10,526,000 shares priced at US$4.75 per share with a US$0.285 discount per share.Narratiefupdate • Jul 21
SOPH: AI Usage Model And NHS Rollout Will Drive Future Upside
Analysts have raised their price target on SOPHiA GENETICS stock to $12, citing the company’s AI-driven, usage-based revenue model across clinical and biopharma customers, as well as its exposure to an estimated $40 billion addressable market, as key factors supporting the updated valuation and fair value assumptions. What’s in the News for SOPHiA GENETICS SOPHiA GENETICS completed a follow on equity offering of 10,526,000 common shares at US$4.75 per share, raising approximately US$49.9985 million.Seeking Alpha • Jun 18
SOPHiA Genetics: Strong Growth Meets A Critical Execution Phase
Summary SOPHiA GENETICS is approaching an inflection point in precision medicine, leveraging AI-driven genomic analysis as sequencing costs decline and data complexity rises. SOPH's platform benefits from a self-reinforcing data flywheel, with 2.5 million genomic profiles and 537 institutions using SOPHiA DDM across 75 countries. Revenue grew 22% year-over-year to $21.7M in 1Q26, with 117% net dollar retention and adjusted gross margin of 75.4%, but profitability remains a key watchpoint. Management targets adjusted EBITDA breakeven by end-2026 and profitability in 2027, supported by cost discipline, new high-value applications, and expanding customer adoption. Read the full article on Seeking Alpha
Narratiefupdate • Jun 15
SOPH: New Partnerships And Ai Collaboration Will Support Future Precision Oncology
Analysts have increased their price target on SOPHiA GENETICS by $1, reflecting updated views on fair value, discount rate, revenue growth, profit margin and future P/E assumptions. What's in the News SOPHiA GENETICS signed a Memorandum of Understanding with Memorial Sloan Kettering Cancer Center to form a joint venture that aims to combine Memorial Sloan Kettering Cancer Center clinical data with the SOPHiA DDM Ai platform for multimodal precision oncology research and deployment.Narratiefupdate • Jun 01
SOPH: NHS Liquid Biopsy Rollout Will Support Future Upside Potential
Analysts have lifted their price target on SOPHiA GENETICS by $1, citing updated models that reflect a lower discount rate, adjusted revenue growth and profit margin assumptions, and a revised future P/E estimate. What's in the News SOPHiA GENETICS partnered with Synnovis, a leading pathology provider in England, to roll out liquid biopsy testing for lung and breast cancer patients across the U.K. under NHS England's blood test first program, using the MSK-ACCESS® test powered by SOPHiA DDM™.Narratiefupdate • May 15
SOPH: New NHS Partnerships Will Support Future Precision Oncology Adoption
Analysts recently lifted their price target on SOPHiA GENETICS by $1, citing updated assumptions around fair value, discount rate, revenue growth, profit margin and future P/E that together support a slightly higher valuation framework for the stock. Analyst Commentary Recent research has framed the updated price target as a fine tuning of prior assumptions rather than a major shift in conviction.Narratiefupdate • Apr 24
SOPH: Higher Future P/E Assumptions Will Support Upside Potential
Analysts lifted their price target on SOPHiA GENETICS by about $0.33 to $8.00, citing updated assumptions around fair value, discount rate, and future P/E that reflect recent research from multiple firms. Analyst Commentary Recent Street research has pointed to updated assumptions around fair value, the discount rate, and forward P/E as the main drivers behind the refreshed $8.00 price target on SOPHiA GENETICS.Narratiefupdate • Apr 09
SOPH: New U.S. Health System Partnerships Will Drive Future Upside
Analysts have raised their price target on SOPHiA GENETICS by $1, reflecting updated views on the company’s discount rate, revenue growth outlook, profit margin assumptions, and future P/E as highlighted in recent Street research. Analyst Commentary Recent Street research around SOPHiA GENETICS points to a more cautious tone, even as price targets are adjusted to reflect updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples.Narratiefupdate • Mar 26
SOPH: Higher Future P/E And New U.S. Partnerships Will Support Upside
Analysts raised their price target on SOPHiA GENETICS by $1, reflecting updated views on factors such as revenue growth expectations, discount rate assumptions, profit margin outlook, and a recalibrated future P/E multiple. Analyst Commentary Bullish Takeaways Bullish analysts see the higher price target as better aligning the stock with updated expectations for revenue growth, which they view as supportive of a richer valuation multiple.Narratiefupdate • Mar 11
SOPH: New US Health System Deals Will Support Future Upside
Analysts lifted their fair value estimate for SOPHiA GENETICS by $1.00 to $7.00, citing updated assumptions for growth, profitability, and future P/E that align with the recent $1 upward move in the Street price target. Analyst Commentary While the latest fair value move to $7.00 lines up with the recent Street price target adjustment, not everyone is leaning positive.Narratiefupdate • Feb 25
SOPH: Higher Implied P/E And New Partnerships Will Support Future Platform Adoption
Analysts have raised their price target on SOPHiA GENETICS by $1, citing updated assumptions on discount rate and long term profitability that result in a slightly higher implied future P/E of 79.26x. Analyst Commentary Analysts raising the price target by $1 are essentially saying that, based on their updated models, the shares now justify a slightly richer valuation, reflected in the implied future P/E of 79.26x.Narratiefupdate • Feb 10
SOPH: Oncology Collaboration And New Leadership Will Support Future Platform Adoption
Analysts have nudged their price target on SOPHiA GENETICS higher by about US$1, reflecting updated views on the company that are consistent with recent Street research commentary. Analyst Commentary Bullish Takeaways Bullish analysts connect the roughly US$1 price target adjustment to refreshed expectations on how SOPHiA GENETICS can execute on its roadmap.Narratiefupdate • Jan 27
SOPH: Higher Price Work Will Highlight Expanding Oncology Collaborations
Analysts have increased their price target on SOPHiA GENETICS by US$1, citing updated assumptions around fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts lifting their fair value assumptions by US$1 are essentially fine tuning how they see SOPHiA GENETICS balancing growth potential, execution risk, and valuation multiples such as P/E over time.Analyse-artikel • Sep 30
Market Participants Recognise SOPHiA GENETICS SA's (NASDAQ:SOPH) Revenues Pushing Shares 28% Higher
SOPHiA GENETICS SA ( NASDAQ:SOPH ) shares have continued their recent momentum with a 28% gain in the last month alone...Analyse-artikel • Aug 08
Analysts Are Updating Their SOPHiA GENETICS SA (NASDAQ:SOPH) Estimates After Its Second-Quarter Results
NasdaqGS:SOPH 1 Year Share Price vs Fair Value Explore SOPHiA GENETICS's Fair Values from the Community and select...Narratiefupdate • Aug 06
Precision Medicine Advances Will Transform Global Healthcare Analytics
SOPHiA GENETICS' consensus price target has been reduced to $6.75, primarily reflecting lowered revenue growth expectations despite a modest improvement in net profit margin. What's in the News SOPHiA GENETICS reiterated its full-year 2025 revenue guidance of $72 million to $76 million.Analyse-artikel • Jul 10
Revenues Tell The Story For SOPHiA GENETICS SA (NASDAQ:SOPH) As Its Stock Soars 29%
SOPHiA GENETICS SA ( NASDAQ:SOPH ) shareholders have had their patience rewarded with a 29% share price jump in the...
Nieuw narratief • Apr 02
Expedited Implementation And New US Signings Will Boost Future Impact
Expansion in the U.S. market and major new customer acquisitions like Mount Sinai are poised to significantly boost revenue and market share.Analyse-artikel • Mar 20
With A 25% Price Drop For SOPHiA GENETICS SA (NASDAQ:SOPH) You'll Still Get What You Pay For
SOPHiA GENETICS SA ( NASDAQ:SOPH ) shareholders won't be pleased to see that the share price has had a very rough...Analyse-artikel • Jan 10
Shareholders Should Be Pleased With SOPHiA GENETICS SA's (NASDAQ:SOPH) Price
When close to half the companies in the Healthcare Services industry in the United States have price-to-sales ratios...Analyse-artikel • Oct 03
Is SOPHiA GENETICS (NASDAQ:SOPH) A Risky Investment?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyse-artikel • Aug 09
SOPHiA GENETICS SA (NASDAQ:SOPH) Just Reported, And Analysts Assigned A US$6.00 Price Target
Shareholders in SOPHiA GENETICS SA ( NASDAQ:SOPH ) had a terrible week, as shares crashed 25% to US$3.36 in the week...Analyse-artikel • Aug 08
Investors Still Waiting For A Pull Back In SOPHiA GENETICS SA (NASDAQ:SOPH)
When you see that almost half of the companies in the Healthcare Services industry in the United States have...Rendement voor aandeelhouders
| SOPH | US Healthcare Services | US Markt | |
|---|---|---|---|
| 7D | -7.2% | -7.0% | -0.2% |
| 1Y | 132.0% | -18.8% | 14.8% |
Rendement versus industrie: SOPH overtrof de US Healthcare Services industrie, die het afgelopen jaar een rendement -18.8 % opleverde.
Rendement versus markt: SOPH overtrof de US markt, die het afgelopen jaar een rendement opleverde van 14.8 %.
Prijsvolatiliteit
| SOPH volatility | |
|---|---|
| SOPH Average Weekly Movement | 10.8% |
| Healthcare Services Industry Average Movement | 9.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.5% |
| 10% least volatile stocks in US Market | 2.9% |
Stabiele aandelenkoers: De aandelenkoers van SOPH is de afgelopen 3 maanden volatiel geweest in vergelijking met de US markt.
Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 11% ) van SOPH is het afgelopen jaar stabiel geweest, maar is nog steeds hoger dan 75% van de aandelen US.
Over het bedrijf
| Opgericht | Werknemers | CEO | Website |
|---|---|---|---|
| 2011 | 415 | Ross Muken | www.sophiagenetics.com |
SOPHiA GENETICS SA is actief als een cloud-native softwaretechnologiebedrijf in de gezondheidszorgsector. Het bedrijf biedt het SOPHiA DDM-platform aan, een cloud-native softwareplatform voor het analyseren van gegevens en het genereren van inzichten uit multimodale datasets en diagnostische modaliteiten. Het SOPHiA DDM-platform en de bijbehorende oplossingen, applicaties, producten en diensten worden gebruikt door ziekenhuizen, laboratoria en biofarmaceutische bedrijven via het eigen verkoopteam, maar ook via distributeurs en samenwerkingspartners in Zwitserland, Frankrijk, Italië, de rest van Europa, Noord-Amerika, de Verenigde Staten, Latijns-Amerika en de Aziatisch-Pacifische regio.
SOPHiA GENETICS SA Samenvatting
| SOPH fundamentele statistieken | |
|---|---|
| Marktkapitalisatie | US$711.67m |
| Inkomsten(TTM) | -US$80.88m |
| Inkomsten(TTM) | US$86.17m |
7.6x
P/S-verhouding-8.1x
Koers/WinstverhoudingIs SOPH overgewaardeerd?
Zie Reële waarde en waarderingsanalyseInkomsten en omzet
| SOPH resultatenrekening (TTM) | |
|---|---|
| Inkomsten | US$86.17m |
| Kosten van inkomsten | US$28.76m |
| Brutowinst | US$57.41m |
| Overige uitgaven | US$138.29m |
| Inkomsten | -US$80.88m |
Laatst gerapporteerde inkomsten
Jun 30, 2026
Volgende inkomensdatum
n.v.t.
| Winst per aandeel (EPS) | -0.95 |
| Brutomarge | 66.63% |
| Nettowinstmarge | -93.86% |
| Schuld/Eigen Vermogen Verhouding | 57.7% |
Hoe presteerde SOPH op de lange termijn?
Bekijk historische prestaties en vergelijkingBedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/09/09 10:50 |
| Aandelenkoers aan het einde van de dag | 2026/09/09 00:00 |
| Inkomsten | 2026/06/30 |
| Jaarlijkse inkomsten | 2025/12/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysamodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina, we hebben ook handleidingen over hoe u onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
SOPHiA GENETICS SA wordt gevolgd door 7 analisten. 5 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Mark Massaro | BTIG |
| William Bonello | Craig-Hallum Capital Group LLC |
| Subhalaxmi Nambi | Guggenheim Securities, LLC |